Pipeline
Pipeline Overview
We have assembled a robust portfolio of allogeneic, iPSC-derived cell therapies in autoimmune disease and cancer. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
Product
Targets
Indications
Clinical Trial
Research
IND-enabling
Clinical
Phase 1
Phase 2
Phase 3
Hematologic tumors
Solid Tumors
Autoimmune Diseases
1Agreement in place for an investigator sponsored trial (IST) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.
CNTY-813
CNTY-813 is comprised of iPSC-derived beta islets engineered with Allo-Evasion™ 5.0 and designed to protect from T cell, NK cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression. CNTY-813 is being developed as a potential treatment for type 1 diabetes.
CNTY-308
CNTY-308 is a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy functionally comparable to primary T cells and engineered with Allo-Evasion™ 5.0. CNTY-308 is being developed as a potential treatment for B-cell-mediated diseases.
CNTY-101
CNTY-101 is a CAR-iNK cell therapy with six precision gene edits as a potential treatment for patients with B-cell-mediated autoimmune diseases.